We reply within one business dayGet my quote
Wet (neovascular) age-related macular degeneration (wet AMD): US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Wet age-related macular degeneration: the short answer
The US FDA has approved four medicines on this page for wet age-related macular degeneration, each for specific patients. Four of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Eylea, Vabysmo, Lucentis and Beovu.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is wet age-related macular degeneration?
Age-related macular degeneration (AMD) is a leading cause of vision loss in older people. It damages the macula, the part of the eye needed for sharp central vision, reading and driving. It does not hurt.[1]
There are two types. In wet AMD, abnormal blood vessels grow under the macula and leak blood and fluid, damaging it quickly. Blurred vision is a common early symptom. In 10 to 15 percent of people, the more common dry form progresses to the wet form.[1, 2]
Regular eye exams can find AMD before vision is lost. Treatment can slow vision loss but does not restore vision. For wet AMD, US-approved medicines that block VEGF are injected into the eye at regular intervals.[1, 3, 4]
Wet age-related macular degeneration in the Gulf
A review of 1,935 patients at the retina clinic of King Abdulaziz University Hospital in Jeddah found AMD in 4%. Age, family history, smoking and high blood pressure were significantly linked with AMD.[5]
US FDA-approved medicines for wet age-related macular degeneration
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Eylea (aflibercept)
FDA-approved for patients with neovascular (wet) AMD and other retinal conditions listed in the label. It is injected into the eye by an eye specialist.[3]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
Country guides: Saudi Arabia, UAE, Egypt, India, Pakistan - Vabysmo (faricimab)
FDA-approved for patients with neovascular (wet) AMD and other retinal conditions listed in the label. It blocks VEGF and angiopoietin-2 and is injected into the eye.[4]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Egypt, Jordan, India, Pakistan - Lucentis (ranibizumab)
FDA-approved for patients with neovascular (wet) AMD and other retinal conditions listed in the label. It is injected into the eye.[8]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
Country guides: Saudi Arabia, UAE, Egypt, India, Pakistan - Beovu (brolucizumab)
FDA-approved for patients with neovascular (wet) AMD and diabetic macular edema. It is injected into the eye.[9]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
Country guides: Saudi Arabia, UAE, Egypt, India, Pakistan
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[10, 11] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for wet age-related macular degeneration
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for wet age-related macular degeneration?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Eylea, Vabysmo, Lucentis and Beovu. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Eylea available in Saudi Arabia or the UAE?
Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Eylea?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Will treatment bring my vision back?
MedlinePlus explains that treatment can slow vision loss but does not restore vision, which is why early diagnosis and regular injections matter.
Are these eye injections available in the Gulf?
Several are listed in Gulf registers. Check the register line under each medicine. Hospital eye departments often stock them.
Sources for the last two answers: [1] [6, 7]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus (US National Library of Medicine): Macular Degeneration
- MedlinePlus Genetics (US National Library of Medicine): Age-related macular degeneration
- DailyMed (US National Library of Medicine): Eylea (aflibercept) US prescribing information, version published 23 July 2026
- DailyMed (US National Library of Medicine): Vabysmo (faricimab) US prescribing information, version published 22 April 2026
- Abusharkh et al. Prevalence and Associated Risk Factors of Age-Related Macular Degeneration in the Retina Clinic at a Tertiary Center in Makkah Province, Saudi Arabia: A Retrospective Record Review. Cureus 2023 (PubMed 37056542)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed (US National Library of Medicine): Lucentis (ranibizumab) US prescribing information, version published 26 November 2025
- DailyMed (US National Library of Medicine): Beovu (brolucizumab) US prescribing information, version published 17 November 2025
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Stargardt disease
- Retinitis pigmentosa
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
This page is general health information, not medical advice. It does not replace a consultation with your doctor.